MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.1/17.01.25 | Market Closed - Bid/Ask 06:20:15 01/07/2024 pm IST | After market 11:32:39 pm | |||
| 2.85 EUR | -1.72% |
|
3.025 | +6.14% |
| Current month | +32.42% | ||
| 1 month | +31.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 2.85 | -1.72% |
| 28/24/28 | 2.9 | -1.36% |
| 27/24/27 | 2.94 | 0.00% |
| 26/24/26 | 2.94 | -5.77% |
| 25/24/25 | 3.12 | +13.45% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 06:20 pm IST
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GB6 |
| ISIN | DE000ME1GB69 |
| Date issued | 03/10/2023 |
| Strike | 120 $ |
| Maturity | 17/01/2025 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 0.57 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.12 € |
|---|---|
| Lowest since issue | 0.43 € |
| Delta | 0.83x |
| Omega | 3.678 |
| Premium | 4.76x |
| Gearing | 4.45x |
| Moneyness | 1.215 |
| Difference Strike | -25.51 $ |
| Difference Strike % | -21.26% |
| Spread | 0.01 € |
| Spread % | 0.33% |
| Theoretical value | 3.045 |
| Implied Volatility | 36.26 % |
| Total Loss Probability | 24.66 % |
| Intrinsic value | 2.397 |
| Present value | 0.6477 |
| Break even | 152.67 € |
| Theta | -0.02x |
| Vega | 0.03x |
| Rho | 0.04x |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.49%
- Stock Market
- Warrants
- Warrant
